Candel Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Candel Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
Candel Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 369 %, a 430% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	369	+299	+430%	Jun 30, 2024
Q1 2024	150	+87.9	+142%	Mar 31, 2024
Q4 2023	105	+44.7	+74.7%	Dec 31, 2023
Q3 2023	79.7	+26	+48.4%	Sep 30, 2023
Q2 2023	69.5	+18.1	+35.2%	Jun 30, 2023
Q1 2023	62	-19.7	-24.2%	Mar 31, 2023
Q4 2022	59.9			Dec 31, 2022
Q3 2022	53.7			Sep 30, 2022
Q2 2022	51.4			Jun 30, 2022
Q1 2022	81.7			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.